These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38755140)

  • 1. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
    Johnson TS; Sudha P; Liu E; Becker N; Robertson S; Blaney P; Morgan G; Chopra VS; Dos Santos C; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
    Nat Commun; 2024 May; 15(1):4144. PubMed ID: 38755140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma.
    Johnson TS; Sudha P; Liu E; Blaney P; Morgan G; Chopra VS; Santos CD; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
    Res Sq; 2023 Aug; ():. PubMed ID: 37645789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.
    Yu T; Du C; Ma X; Sui W; Yu Z; Liu L; Zhao L; Li Z; Xu J; Wei X; Zhou W; Deng S; Zou D; An G; Tai YT; Tricot G; Anderson KC; Qiu L; Zhan F; Hao M
    Mol Cancer Res; 2020 Jul; 18(7):1063-1073. PubMed ID: 32312841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PHD finger protein 19 expression in multiple myeloma: Association with clinical features, induction therapy outcome, disease progression, and survival.
    Li Y; Gong J; Zhang L
    J Clin Lab Anal; 2021 Sep; 35(9):e23910. PubMed ID: 34390275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.
    Ziccheddu B; Biancon G; Bagnoli F; De Philippis C; Maura F; Rustad EH; Dugo M; Devecchi A; De Cecco L; Sensi M; Terragna C; Martello M; Bagratuni T; Kastritis E; Dimopoulos MA; Cavo M; Carniti C; Montefusco V; Corradini P; Bolli N
    Blood Adv; 2020 Mar; 4(5):830-844. PubMed ID: 32126144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma.
    Bolomsky A; Ceribelli M; Scheich S; Rinaldi K; Huang DW; Chakraborty P; Pham L; Wright GW; Hsiao T; Morris V; Choi J; Phelan JD; Holewinski RJ; Andresson T; Wisniewski J; Riley D; Pittaluga S; Hill E; Thomas CJ; Muppidi J; Young RM
    Cancer Cell; 2024 Jul; 42(7):1185-1201.e14. PubMed ID: 38906156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.
    Ghamlouch H; Boyle EM; Blaney P; Wang Y; Choi J; Williams L; Bauer M; Auclair D; Bruno B; Walker BA; Davies FE; Morgan GJ
    J Exp Clin Cancer Res; 2021 Dec; 40(1):380. PubMed ID: 34857028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.
    Sherbenou DW; Aftab BT; Su Y; Behrens CR; Wiita A; Logan AC; Acosta-Alvear D; Hann BC; Walter P; Shuman MA; Wu X; Atkinson JP; Wolf JL; Martin TG; Liu B
    J Clin Invest; 2016 Dec; 126(12):4640-4653. PubMed ID: 27841764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
    Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
    Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
    Mohan M; Weinhold N; Schinke C; Thanedrarajan S; Rasche L; Sawyer JR; Tian E; van Rhee F; Zangari M
    Br J Haematol; 2020 Apr; 189(1):67-71. PubMed ID: 31820442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma.
    Balcárková J; Urbánková H; Scudla V; Holzerová M; Bacovský J; Indrák K; Jarosová M
    Cancer Genet Cytogenet; 2009 Jul; 192(2):68-72. PubMed ID: 19596256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
    Mason MJ; Schinke C; Eng CLP; Towfic F; Gruber F; Dervan A; White BS; Pratapa A; Guan Y; Chen H; Cui Y; Li B; Yu T; Chaibub Neto E; Mavrommatis K; Ortiz M; Lyzogubov V; Bisht K; Dai HY; Schmitz F; Flynt E; Dan Rozelle ; Danziger SA; Ratushny A; ; Dalton WS; Goldschmidt H; Avet-Loiseau H; Samur M; Hayete B; Sonneveld P; Shain KH; Munshi N; Auclair D; Hose D; Morgan G; Trotter M; Bassett D; Goke J; Walker BA; Thakurta A; Guinney J
    Leukemia; 2020 Jul; 34(7):1866-1874. PubMed ID: 32060406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
    Slomp A; Moesbergen LM; Gong JN; Cuenca M; von dem Borne PA; Sonneveld P; Huang DCS; Minnema MC; Peperzak V
    Blood Adv; 2019 Dec; 3(24):4202-4214. PubMed ID: 31856269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
    Ling SC; Lau EK; Al-Shabeeb A; Nikolic A; Catalano A; Iland H; Horvath N; Ho PJ; Harrison S; Fleming S; Joshua DE; Allen JD
    Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.
    He H; Li Z; Lu J; Qiang W; Jiang S; Xu Y; Fu W; Zhai X; Zhou L; Qian M; Du J
    Clin Transl Med; 2022 Mar; 12(3):e757. PubMed ID: 35297204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-evolution of tumor and immune cells during progression of multiple myeloma.
    Liu R; Gao Q; Foltz SM; Fowles JS; Yao L; Wang JT; Cao S; Sun H; Wendl MC; Sethuraman S; Weerasinghe A; Rettig MP; Storrs EP; Yoon CJ; Wyczalkowski MA; McMichael JF; Kohnen DR; King J; Goldsmith SR; O'Neal J; Fulton RS; Fronick CC; Ley TJ; Jayasinghe RG; Fiala MA; Oh ST; DiPersio JF; Vij R; Ding L
    Nat Commun; 2021 May; 12(1):2559. PubMed ID: 33963182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.
    Munawar U; Roth M; Barrio S; Wajant H; Siegmund D; Bargou RC; Kortüm KM; Stühmer T
    Sci Rep; 2019 Dec; 9(1):18062. PubMed ID: 31792264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
    Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.